Dermata Therapeutics Statistics
Total Valuation
DRMA has a market cap or net worth of $4.83 million. The enterprise value is -$2.70 million.
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026, before market open.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DRMA has 4.02 million shares outstanding. The number of shares has increased by 505.46% in one year.
| Current Share Class | 4.02M |
| Shares Outstanding | 4.02M |
| Shares Change (YoY) | +505.46% |
| Shares Change (QoQ) | +10.16% |
| Owned by Insiders (%) | 20.96% |
| Owned by Institutions (%) | 7.35% |
| Float | 2.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.51 |
| P/TBV Ratio | 0.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.79
| Current Ratio | 4.79 |
| Quick Ratio | 4.59 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -194.20% and return on invested capital (ROIC) is -124.83%.
| Return on Equity (ROE) | -194.20% |
| Return on Assets (ROA) | -85.25% |
| Return on Invested Capital (ROIC) | -124.83% |
| Return on Capital Employed (ROCE) | -124.91% |
| Weighted Average Cost of Capital (WACC) | 7.54% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$944,820 |
| Employee Count | 8 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.89% in the last 52 weeks. The beta is 0.60, so DRMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | -88.89% |
| 50-Day Moving Average | 1.56 |
| 200-Day Moving Average | 3.83 |
| Relative Strength Index (RSI) | 43.24 |
| Average Volume (20 Days) | 2,388,001 |
Short Selling Information
The latest short interest is 43,939, so 1.09% of the outstanding shares have been sold short.
| Short Interest | 43,939 |
| Short Previous Month | 112,575 |
| Short % of Shares Out | 1.09% |
| Short % of Float | 1.50% |
| Short Ratio (days to cover) | 0.02 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -7.77M |
| Pretax Income | -7.56M |
| Net Income | -7.56M |
| EBITDA | n/a |
| EBIT | -7.77M |
| Earnings Per Share (EPS) | -$8.16 |
Full Income Statement Balance Sheet
The company has $7.52 million in cash and n/a in debt, with a net cash position of $7.52 million or $1.87 per share.
| Cash & Cash Equivalents | 7.52M |
| Total Debt | n/a |
| Net Cash | 7.52M |
| Net Cash Per Share | $1.87 |
| Equity (Book Value) | 6.22M |
| Book Value Per Share | 2.34 |
| Working Capital | 6.22M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -7.76M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DRMA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -505.46% |
| Shareholder Yield | -505.46% |
| Earnings Yield | -156.60% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for DRMA is $10.00, which is 733.33% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 733.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 1, 2025. It was a reverse split with a ratio of 1:10.
| Last Split Date | Aug 1, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |